¼ÐÃD: ÂåÃĪÑ
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.95.76
¤À¨É 
µoªí©ó 2014-9-15 15:55  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
ÂåÃĪÑ



  1. ¿Õ©M¿Õ¼w
  2. '¿Õ©M¿Õ¼w'¬O¤@®a¥»³¡¦ì©ó¤¦³Áªº»sÃÄ¥ø·~¡C¤½¥q¦b¿}§¿¯f»â°ì¡B¥Íªø¿E¯À»â°ì¡B¦å¤Í¯f»â°ì´£¨Ñ»s«~©MªA°È¡C ºû°ò¦Ê¬ì
  3. ªÑ»ù¡G NVO (NYSE) $45.87 +0.36 (+0.79%)
    8¤ë26¤é ¤U¤È4:02 GMT-4 - §K³dÁn©ú
  4. Á`³¡¡G ¤¦³Á
  5. ¦¨¥ß©ó¡G 1923 ¦~
  6. ¿Õ©M¿Õ¼w¤½¥q¾Ö¦³³Ì¥ý¶iªº¯Ø®q¯À²£«~¡A§Ú­Ì¦b¯Ø®q¯À¤Î¿}§¿¯f·ÓÅ@»â°ì¦ì©~»â¾É¦a¦ì¡A§Ú­Ìªº¥Ø¼Ð¦b©ó´M§ä³Ì¦nªº¹w¨¾»PªvÀø¤èªk¾Ô³Ó¿}§¿¯f¡A¨Ã´£¤É±wªÌªº¥Í¬¡«~½è¦¹¥~¡A¿Õ©M¿Õ¼w¦b¤î¦åºÞ²z¡B¥Íªø¿E¯À¥H¤Î¶Pº¸»X¸É¥RÀøªkµ¥¦h¤è­±¦³¥ç¦³¨ô¶Vªºµo®i¡C



§Ú­Ìªº¾ú¥v

¿Õ©M¿Õ¼w¤½¥qªº¾ú¥v¥i°l·¹¨ì80¦h¦~«e¤@¹ï¤¦³Á¤Ò°üªº¤@¦¸¬ü°ê¤§®È¡C1922¦~¡AAugust KroghÄâ©d¤lMarie ¨ì¬ü°ê®È¦æ¡CAugust¬O­ô¥»«¢®Ú¤j¾Çªº¤@¦ì±Ð±Â¡AÀò±o¹L¥Í²z¾Ç¿Õ¨©º¸¼ú¡C¥Lªº©d¤lMarie¬O¤@¦W¬ã¨s·s³¯¥NÁªºÂå®v¡A¦P®É¤]¬O¤@¦ì²Ä2«¬¿}§¿¯f±wªÌ¡C


®È¬ü´Á¶¡¡AKrogh¤Ò°üÅ¥»¡¡A¦³¨â¦ì¥[®³¤j¬ì¾Ç®aFrederick Banting©MCharles Best¥¿¦b¥Î±q¤û¯ØŦ´£¨ú¥Xªº¯Ø®q¯À¬°±wªÌªvÀø¿}§¿¯f¡CKrogh¤Ò°ü¹ï¦¹«D±`·P¿³½ì¡A¦]¬°Krogh¤Ò¤H¥»¤H´N±w¦³¿}§¿¯f¡C³Ì²×¡A¥L­ÌÀò±o¤F¦b¤¦³Á¥Í²£¯Ø®q¯Àªº³\¥iÅv¡C


¦^¨ì¤¦³Á«á¡AKrogh¥ß§Y»P¦å¿}½Õ¸`±M®aH C Hagedorn±Ð±Â¤@°_°Q½×¦¹¨Æ¡A¨Ã¨M©w¶i¦æ§ó¥[²`¤Jªº¬ã¨s¡CµM«á¡A¥L­Ì«ô³X¤F¤¦³ÁÃľ¯®vAugust Kongsted¡CAugust Kongsted¦P·N´£¨Ñ¬ã¨s¶O¥Î¡A¨ÃÀ°§U±Ò°Ê¯Ø®q¯À¥Í²£¡C1922¦~12¤ë21¤é¡AKrogh©MH C Hagedorn±Ð±Â¦¨¥\¦a±q¤û¯ØŦ¤¤´£¨ú¥X¤F¤Ö¶q¯Ø®q¯À¡C1923¦~3¤ë¡A²Ä¤@§å±wªÌ¥Î¥L­Ì©Ò¥Í²£ªº¯Ø®q¯À¶i¦æ¤FªvÀø¡C1923¦~¬K©u¡A¥L­Ì¦¨¥ß¤F¿Õ¼w¯Ø®q¯À¹êÅç«Ç(§Y¿Õ¼w¤½¥q)¡C


1923¦~¡A¤uµ{®vHarald Pedersen¥[¤J¿Õ¼w¤½¥q¡A¬°¤½¥q»s³y¯Ø®q¯À¥Í²£¾÷¾¹¡C«á¨Ó¡A¥Lªº§Ì§ÌThorvald Pedersen¤]¨ü¸u©ó¿Õ¼w¤½¥q¡A­t³d¯Ø®q¯À¥Í²£¤¤ªº¤Æ¾Ç¹Lµ{¤ÀªR¡CµM¦Ó¡AThorvald Pedersen»PHagedorn¬Û³B¤£¦n¡A¨Ã©ó1924¦~³QHagedorn¶}°£¡C¥X©ó¹ï¥S§Ì±¡½Ëªº©¾¸Û¡AHarald Pedersen»¼¥æ¤FÃã§e¡A¨Ã»P§Ì§Ì¤@°_¦¨¥ß¤F¦Û¤vªº¤½¥q¡C¨ì1924¦~¡A¥L­Ì¤]¦¨¥\¦a¥Í²£¥X¯Ø®q¯À¡C1925¦~¡A¥S§Ì¤G¤Hµ¹¤¦³ÁªºÃľ¯®v¨ó·|±H¤F¤@«Ê«H¡A§iª¾¥L­Ì¡§¿Õ©M¡¨¯Ø®q¯À¤Î¡§¿Õ©M¡¨ª`®g¾¹¶}©l¤W¥«¾P°â¡C¥S§Ì­Ç±N¥L­Ìªº¤½¥q©R¦W¬°¡§¿Õ©MTerapeutisk¹êÅç«Ç¡¨(§Y¿Õ©M¤½¥q)¡C¦Ü¦¹¡A¤¦³Á¦³¤F¨â®a§Y±Nµo®i¦¨¬°¥@¬É¯Ø®q¯À»s³y»â°ì¥ý¾Éªº¤½¥q¡C


¦b±µ¤U¨Óªº65¦~¤¤¡A¨â®a¤½¥q³£¨³³tµo®i¡A¯É¯É«Ø¥ß¤j«¬¬ã¨s¾÷ºc¡A¨Ã¬°¾Ö¦³¿}§¿¯fªvÀø·s²£«~¡B¦û¾Ú¥«³õº]­º¶i¦æ¤F¿E¯PªºÄvª§¡C¦P®É¡A¿Õ¼w¤½¥q©M¿Õ©M¤½¥q¤]¶}©l³z¹L¶}µo¨ä¥¦²£«~¹ê²{¦U¦Ûªº¦h¼Ë¤Æµo®i¡C¿Õ©M¤½¥q¦¨¬°¤F¥@¬É³Ì¤jªº¤u·~»s¾¯¥Í²£°Ó¡A¦Ó¿Õ¼w¤½¥q«h¶}µo¥X¦å¤Í¯fªvÀøÃĪ«¤Î¥Íªø«O°·²£«~¡C


1989¦~1¤ë¡A¿Õ©M©M¿Õ¼w¨â®a¤½¥q¨M©w¦X¨Ö¡C¦Ü¦¹¡A¸g¾ú¤F60¦h¦~ªºÄvª§¸û¶q¤§«á¡AÂù¤è²×©ó±È¶}¤F¦P¤ß¨ó¤O¶}µo¿}§¿¯fªvÀø·s²£«~¡B©º¾Ô°ê»Ú¥«³õªº·s½g³¹¡C¦X¨Ö«áªº·s¤½¥q´N¬O¿Õ©M¿Õ¼w¤½¥q¡C


1999¦~ªì¡A¿Õ©M¿Õ¼w¤½¥q¨M©w«ö·Ó¤½¥qªº¨â­Ó®Ö¤ß·~°È¢w°·±dÂåÀø©M»Ã¯À²£«~·~°È¡A±N¤½¥q©î¤À¬°¨â­Ó¿W¥ß¸gÀç¾÷ºc¡C¦¹¦¸¤À®a¨Ï¨â­Ó¾÷ºc¯à°÷¾Ö¦³§ó¤jªº¸gÀç¦Û¥Ñ¡A¦b¦U¦ÛÀu¶Õ»â°ì³Ð³y½÷·×¡C2000¦~11¤ë14¤é¡A¿Õ©M¿Õ¼w¤½¥q©M¿Õºû«H¤½¥q¶}©l¤F¥¦­Ì¿W¥ß¸gÀ窺·s½g³¹¡C´N³o¼Ë¡A¬üÄRªº¬G¨Æ·s½g¤S±q¦¹©µÄò¤U¥h...
³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.95.76
µoªí©ó 2014-9-15 15:55  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 

¿Õºû«H¬O¤Þ»â¥Íª«³Ð·sªº¥@¬É¥ý¾É¡AÁ`³¡¦ì©ó¤¦³Á­º³£­ô¥»«¢®Ú¡C§Ú­Ì»P²³¦h¦æ·~«È¤áÄâ¤â¡A¶}µo­±¦V¥¼¨Óªº¤u·~¥Íª«¸Ñ¨M¤è®×¡A«P¶i«È¤á·~°Èµo®i¡A§ï¶i¦a²y¸ê·½ªº¨Ï¥Î¤è¦¡¡C¿Õºû«Hªº700¦hºØ産«~¹M¤Î¥þ²y130­Ó°ê®a¡A¥@¬É¥«³õ¥÷ÃB¶W¹L40%¡C

    ¿Õºû«H­P¤O©ó±´¯Á¥Íª«§Þ³N¤Î¨äÀ³¥Î¡Aºc¿v°_¥H·L¥Íª«¿z¿ï¡B°ò¦]§J¶©¤Îªí¹F¡B³J¥Õ½è¤uµ{¡B¥NÁ¤uµ{©MµßºØ§ï¨}µ¥¬°®Ö¤ßªº¥Íª«§Þ³N¥­»O¡C4500¦h¶µ±M§Q¨£ÃÒ¤F§Ú­Ì¹ï¦ÛµM¼ç¤O¥ÃµL¤î¹Òªº±´¯Á¡A®i¥Ü¥X¦ÛµM»P¬ì§Þµ²¦X©Ò産¥Íªº±j¤j¤O¶q¡C

    ¿Õºû«Hªº酶»s¾¯¦b¬~º°¾¯¡B¯¼Â´¡B¾ý¯»¨î¿}¡B¿U®Æ¤A¾J¡B­¹«~¡B¥Ö­²¡B³y¯È¡B°à°sÆC³y©M¹}®Æµ¥¤u·~»â°ì¦³µÛ¼sªxÀ³¥Î¡F³q¹L´À¥N©Î´î¤Ö¦³®`¤Æ¾Ç«~ªº¨Ï¥Î¡A­°§C¤ô¡B¯à·½©M­ì§÷®Æªº®ø¯Ó¡AÀ°§U¥[³t©Î²¤Æ¤uÃÀ¹Lµ{¡A¸`¬ù¦¨¥»¡A´£°ª¸gÀÙ©MÀô¹Ò®Ä¯q¡C
    ¿Õºû«H¥Íª«¤½¥qªº·L¥Íª«産«~³Q¼sªxÀ³¥Î©ó¤½¥Î¤Î®a©~²M¼ä¡B¼o¤ô³B²z¡B¤ô産¾i´Þ¤Î¹A·~µ¥»â°ì¡A¥H²M¼äÀô«Oªº¤è¦¡¦³®Ä¸Ñ¨M¦hºØÀô¹Ò°ÝÃD¡C¥Ø«e¡A¿Õºû«H¤w±N·~°È½d³ò©Ý®i¨ì¥Íª«»E¦Xª«©M¥Íª«ÂåÃĦ¨¤À»â°ì¡C
³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.95.76
µoªí©ó 2014-9-15 16:01  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
  1. ¸¯Äõ¯À¥v§J

  2. ¸¯Äõ¯À¥v§JªÑ¥÷¦³­­¤½¥q¬OÁ`³¡¦ì©ó­^°ê­Û´°ªº¥þ²y²Ä¤T¤jªº»sÃÄ¡B¥Íª«¥H¤Î½Ã¥Í«O°·¤½¥q¡C¸¯Äõ¯À¥v§J¬O¤@®aÂл\§Ü·P¬V¡B¤¤¼Ï¯«¸g¨t²Î¡B©I§l¬ì¡B¸z­G¡þ¥NÁ¡B¸~½F©M¬Ì­]»â°ìªº¥H¬ãµo¬°°ò¦ªº¤½¥q¡C¥¦¦P®ÉÁÙ¥]§t¤F³B©ó»â¥ý¦a¦ìªº¤fµÄ½Ã¥Í«O°·¡AÀç¾i¶¼®Æ©M¤@¨Ç«D³B¤èÃÄ¡C ºû°ò¦Ê¬ì



  1. ªü´µ§Q±d»sÃÄ

  2. ªü´µ¯S±¶§Q±d»sÃĤ½¥q¡A¬O¤@®a¥Ñ·ç¨åªü´µ¯S©Ô¤½¥q©M­^°ê±¶§Q±d¤½¥q©ó1999¦~4¤ë6¤é¦X¨Ö¦Ó¦¨ªº¤j«¬­^·ç¦X¸ê»sÃÄ¥ø·~¡C­^°ê±¶§Q±d¤½¥q¡A1993¦~³Q°µ¬°«Ò°ê¤Æ¾Ç¤u·~¤½¥q¤@³¡¤À¦Ó¤À©î¥X¨Ó¡Cªü´µ¯S±¶§Q±d¤½¥q¬ãµo¡B»s³y¤Î¾P°â¥Î©óªvÀø®ø¤Æ¡B¤ß¦åºÞ¡B¸~½F¡B¤¤¼Ï¯«¸g¡B©I§l¨t²Î¯e¯f¥H¤Î¥Î©ó³Â¾KªºÃĪ«¡C ºû°ò¦Ê¬ì



    1. ½÷·ç

    2. ½÷·ç»sÃĦ³­­¤½¥q¡A¬O¬ü°ê¤@®a¸ó°ê»sÃĤ½¥q¡A¨äÁ`³¡³]©ó¯Ã¬ù¡CºZ¾P²£«~¥]¬A­°Áx©T¾JÃĥߴ¶§´¡B¤fªA§Ü¯uµßÃĤj§ß±d¡B§Ü¥Í¯À§ÆµÎ¬ü¡A¥H¤Îªv¶§·õÃī¦ӿûµ¥¡C¥Ø«e½÷·çÃļt¬O¥@¬É¤W³Ì¤jªºÂåÃÄ¥ø·~¡C ½÷·ç¤½¥qªºªÑ²¼©ó2004¦~4¤ë8¤é¦¨¬°¹Dã´µ¤u·~«ü¼Æªº¦¨¥÷ªÑ¡C ºû°ò¦Ê¬ì




³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.95.76
µoªí©ó 2014-9-15 16:06  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
  1. Àq§JÃļt
  2. Àq§JÃļt¡A¦b¬ü°ê»P¥[®³¤j¤§¥~ªº¦a°ÏºÙ¬°Àq¨FªFÃļt¡Aª¾¦W¬ü°ê»sÃĤ½¥q¡C¸Ó¤½¥qªº«e¨­¬O¦b¼w°ê¹F©i¬I¶ð¯S¦¨¥ßªº¥ì°Ò¯Ãº¸¡PÀq§JÃļt¡C1891¦~Àq§J¬ü°ê¤À¤½¥q¦¨¥ß¡A¦ý¦p¦P³\¦h¦b¬ü°ê¹Ò¤ºªº¼w°ê¥ø·~¸ê²£¤@¯ë¡A¬ü°êÀq§J¤]©ó1917¦~²Ä¤@¦¸¥@¬É¤j¾ÔÃzµo«á¾D¬ü°ê¬F©²¥R¤½¡A¨Ã§ß´Ó¨äÂ૬¦¨¬°¤@¿W¥ß¤½¥qÄ~Äò¸gÀç¡C ºû°ò¦Ê¬ì




  1. Àq§J¶°¹Î

  2. Àq§J¦¨¥ß©ó1668¦~¡A¥ì°Ò¯Ã¡PÀq§J³Ð³]¥þ¥@¬É²Ä¤@®aÃħ½¡A¤µ¤éªºÀq§J¬°¥þ¥@¬É¾ú¥v³Ì±y¤[ªº¤Æ¤u»sÃĤ½¥q¡C Àq§J¶°¹Î³Ð«Ø©ó1668¦~¡A¾Ö¦³¬ù350¦~¾ú¥v¡AÁ`³¡¦ì©ó¼w°ê¹F©i¬I¶ð¯S¥«¡A¸Ó¶°¹Î¥D­n­P¤O©ó³Ð·s«¬»sÃÄ¡B¥Í©R¬ì¾Ç¥H¤Î«eªu¥\¯à§÷®Æ§Þ³N¡CÀq§J¶°¹Î©l²×¥H§Þ³N¬°ÅX°Ê¤O¡A¬°±wªÌ©M«È¤á³Ð³y»ù­È¡C ºû°ò¦Ê¬ì

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.



  1. §¨Ó¤½¥q
  2. §¨Ó¤½¥q¬O¤@®aÁ`³¡³]¦b¬ü°ê¦L²Ä¦w¯Çªi§Q´µªº¥þ²y©Ê»sÃĤ½¥q¡A¦P®É¤]¬O¥þ¥@¬É³Ì¤jªº¥ø·~¤§¤@¡C§¨Ó¤½¥qÁÙ¦bªi¦h¾¤¦U¤Î17­Ó¨ä¥L°ê®a³]¦³¿ì¤½¾÷ºc¡A¨ä²£«~¾P©¹¬ù125­Ó°ê®a¡C1876¦~¥ÑÃľǮaEli Lilly³Ð«Ø¡A¨Ã³Ì²×¥H¥Lªº©m¦W©R¦W¡Cºû°ò¦Ê¬ì
  3. ªÑ»ù¡G [url=https://www.google.com/search?es_sm=122&q=NYSELY&sa=X&ei=Ap0WVL78LM348QXXtYCQBw&ved=0CK8BELEVMA4]LLY[/url] (NYSE) $65.27 +0.09 (+0.14%)
    9¤ë12¤é ¤U¤È4:01 GMT-4 - §K³dÁn©ú
  4. «È¤áªA°È±M½u¡G +1 855-559-8783
  5. Á`³¡¡G ¬ü°ê¦L²Ä¦w¯Ç¦{¦L²Ä¦w¯Çªi§Q´µ
  6. ³Ð¿ì¤H¡G ¥ìµÜ¡P²ú²ú
  7. ¦¨¥ß©ó¡G 1876 ¦~




  1. ¥²ªv§´¬I¶QÄ_
  2. ¥²ªv§´¬I¶QÄ_¬O¬ü°ê¤@®aÂåÃÄ¡BÀç¾i¤Î«O°·²£«~©M¤Æ§©«~¤½¥q¡C ¥²ªv§´¬I¶QÄ_¤½¥q¦b1989¦~¥Ñ¬ü°ê¨â¤j»sÃļt¦Ê®É¬ü©M¬I¶QÄ_¦X¨Ö¦Ó¦¨ªº¡C«eªÌ¦b1887¦~¥Ñ«Â·G¡P³Á©Ô¨Ú¡P¥²ªv§´©M¬ù¿«¡P¨½´¶¹p¡P¬üº¸´µ¦b¯Ã¬ù¦{¶ø©`¹F¿¤¬_ªL¹y§ø¦¨¥ßªº¡A¦Ó¨â¦ì³Ð¿ì¤H³£¬O·í¦aº~À±º¸¹y¾Ç°|ªº²¦·~¥Í¡Cºû°ò¦Ê¬ì



[ ¥»©«³Ì«á¥Ñ chenleon1 ©ó 2014-9-15 16:09 ½s¿è ]
³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.95.76
µoªí©ó 2014-9-15 16:13  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
  1. ¬ü°ê¶®°ö

  2. ¶®°ö¡A¬O¬ü°ê¤W¥«¤½¥q¡A¤]¬O¤@®a¦³72000¦h¤H­û¤uªº¸ó°ê¤½¥q¡AÁ`³¡¦b¥ì§Q¿Õ¦{¡A¦¨¥ß©ó1888¦~¡C­»´ä¶®°ö¼g¦r¼Ó¦b¬¶¥x¤s¹q®ð¹D¤Í¨¹¼s³õ¡C¶®°ö¥H»sÃÄ¡BÂåÀø¾¹§÷»PÀç¾i²£«~¬°¥D­n¨Æ·~¡A¨Ã¦b¶i¦æ¤F´X¦¸¤j«¬ªº¨Æ·~¨ÖÁÊ¡C ºû°ò¦Ê¬ì

  3. ªÑ»ù¡G ABT (NYSE) $42.55 -0.01 (-0.02%)
    9¤ë12¤é ¤U¤È4:00 GMT-4 - §K³dÁn©ú

  4. «È¤áªA°È±M½u¡G +1 847-937-6100

  5. Á`³¡¡G ¬ü°ê¥ì§Q¿Õ¦{

  6. °õ¦æªø¡G ÁÚº¸¤h¡PD¡PÃh¯S

  7. ¦¨¥ß©ó¡G 1888 ¦~






AbbVie (NYSE: ABBV) is a research-based biopharmaceutical company.
On October 19, 2011, Abbott Laboratories announced that it planned to separate into two publicly traded companies, one focused on diversified medical products and the other on research-based pharmaceuticals. The medical products company retained the Abbott name, and the research-based pharmaceuticals company was named AbbVie.
³»³¡
mikeon88
ºÞ²z­û
Rank: 9Rank: 9Rank: 9


UID 1
ºëµØ 0
¿n¤À 0
©«¤l 15453
¾\ŪÅv­­ 255
µù¥U 2007-1-14
¥Î¤áµù¥U¤Ñ¼Æ 6284
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 0

111.243.3.96
µoªí©ó 2014-9-15 16:20  ¸ê®Æ ¥D­¶ ¤å¶° ¨p¤H°T®§ 
«D±`·PÁÂleon®áªº¨¯­W¡A
Åý§Ú­Ì¬Ù¥h¤F³\¦h»`¶°¸ê®Æ©M«ö¬Õ¦Aªíªº®É¶¡¡C

¥t¥~¡Akaka®á½Ð¼·¤¾¨Ó°Ñ¥[¦P¾Ç·|¡A
·|«á¦P§Ú­Ì¤@°_¥ÎÀ\¡A
¥H²áªíÁ§աC
³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.95.76
µoªí©ó 2014-9-15 16:21  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
  1. ù¤ó
  2. ù¤ó¡AÁ`³¡¦ì©ó·ç¤h¤Ú¶ëº¸ªº¸ó°êÂåÃĬãµo¥Í²£°Ó¡C¥¦©l³Ð©ó1896¦~¡A²{ÄÝ©óù¤ó±±ªÑªÑ¥÷¦³­­¤½¥q¡C ù¤ó±±ªÑªÑ¥÷¦³­­¤½¥q¬O­Û´°ÃÒ¨é¥æ©ö©Òvirt-x¤U¤@¤äªÑ²¼¡C2002°]¦~ù¤ó¹ê²{¦¬¤J9.4»õ¬ü¤¸¡C¦ì©~¥þ¥@¬É»sÃĤ½¥q²Ä13¦ì¡C ºû°ò¦Ê¬ì
  3. Á`³¡¡G ·ç¤h¤Ú¶ëº¸



Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In September 2013, Swedish Orphan Biovitrum AB (publ) (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen Inc for all therapeutic indications.




  1. ¿ÕµØ¤½¥q
  2. ¿ÕµØ¤½¥q¬O¤@®aÁ`³¡¦ì©ó·ç¤h¤Ú¶ëº¸ªº»sÃĤΥͪ«§Þ³N¸ó°ê¤½¥q¡C¥¦ªº®Ö¤ß·~°È¬°¦UºØ±M§QÃÄ¡B®ø¶OªÌ«O°·¡B«D±M§QÃÄ¡B²´·úÅ@²z©M°Êª««O°·µ¥»â°ì¡C¿ÕµØ¤½¥q¦¨¥ß©ó1996¦~¡A¥Ñ¦ì©ó¤ÚÁɺ¸ªº¨â®a¤Æ¾Ç«~¤Î»sÃĤ½¥q¡u¨T¤Ú-¹Å°ò¡v©M¡u¤s¼w¤h¡v¦X¨Ö¦Ó¦¨¡C ºû°ò¦Ê¬ì
  3. ªÑ»ù¡G NVS (NYSE) $93.76 -0.60 (-0.64%)
    9¤ë12¤é ¤U¤È4:05 GMT-4 - §K³dÁn©ú
  4. «È¤áªA°È±M½u¡G +1 862-778-2100
  5. Á`³¡¡G ·ç¤h¤Ú¶ëº¸
  1. «ô¦Õ

  2. «ô¦ÕªÑ¥÷¤½¥q¬O¤@®a¤Æ¤u¸ó°ê¶°¹Î¡A¼w°êªÑ²¼«ü¼ÆDAXªº¦¨¤À¤½¥q¡A¥@¬É500±j¤§¤@¡C ºû°ò¦Ê¬ì

  3. ªÑ»ù¡G BAYN (XETRA) £á105.90 -0.25 (-0.24%)
    9¤ë15¤é ¤W¤È10:06 GMT+2 - §K³dÁn©ú

  4. Á`³¡¡G ¼w°êµÜ¨U®w´Ë

  5. ¦¨¥ß©ó¡G 1863 ¦~








[ ¥»©«³Ì«á¥Ñ chenleon1 ©ó 2014-9-15 16:24 ½s¿è ]
³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.90.53
µoªí©ó 2014-9-16 10:15  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc. Effective May 12, 2014, the Company acquired Lumena Pharmaceuticals Inc.

³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.86.83
µoªí©ó 2014-9-19 21:29  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
¤¤°ê¯««ÂÃÄ·~¶°¹Î¦³­­¤½¥q¬O¤¤°ê³Ì¤jªº²{¥N¤¤ÃĪ`®g²G¤Î³n½¦Ån»s³y°Ó¡C¶°¹Î©ó­»´äÁp¦X¥æ©ö©Ò¥DªO¤W¥«¡A¬°ùڥͺî¦X«ü¼Æ¦¨¥÷ªÑ¡A¨Ã³Q¿ï¬°ºÖ¥¬´µ¨È¬w200³Ì¨Î¤¤¤p¥ø·~¤§¤@¡C
¯««ÂÃÄ·~ªº²£«~¥D­n¤À¬°¤¤ÃĪ`®g²G¡B¤¤Ãijn½¦Ån¤Î¤¤ÃÄÁû²É¤T¤jÃþ¡A´£¨Ñ°w¹ï¤¤¦Ñ¦~¤H¡B§Ü¯f¬r¤Î¨àµ£¥ÎÃijo¤T¤j¼ç¤OÀu«p¤§¥«³õ¡C¥»¶°¹Îªº²£«~¤@ª½¥H¨ä¥D­n«~µP¡u¯««Â¡v¾P°â¡A¬°¡u¤¤°ê¹£¦W°Ó¼Ð¡v¡C


http://www.shineway.com.hk/big5/global/home.php



³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.86.83
µoªí©ó 2014-9-20 14:49  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
¶³«n¥ÕÃĬO¤@ºØ¤¤¦¨ÃÄ¡A«ÅºÙ¹ï¶^¥´·l¶Ë¡B³Ð¶Ë¥X¦å¦³«Ü¦nªºÀø®Ä¡C»sÃĤ½¥q¬O¶³«n¥ÕÃĶ°¹ÎªÑ¥÷¦³­­¤½¥q¡]²`¥æ©Ò¡G000538¡^
³»³¡
¥ÕSir
¦P¾Ç




UID 23150
ºëµØ 0
¿n¤À 0
©«¤l 180
¾\ŪÅv­­ 99
µù¥U 2014-9-20
¥Î¤áµù¥U¤Ñ¼Æ 3477
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 445

220.137.39.166
µoªí©ó 2014-9-20 19:04  ¸ê®Æ ¨p¤H°T®§ 
HI ·s¦P¾Ç ¥Õsir³ø¨ì
¸¯Äõ¯À¥v§J¬Q¤Ñ·s»D¥X¨Ó³Q»@$490M ½Ð°Ý·|¼vÅT«U47.4»P¶Q»ù126.8?
¥Ø«e­è¦¬¨ì¬Õ¦Aªí¬ã¨s¤¤, ¦Ò¼{¼½¤U¤@­ÓºØ¤l.....
³»³¡
mikeon88
ºÞ²z­û
Rank: 9Rank: 9Rank: 9


UID 1
ºëµØ 0
¿n¤À 0
©«¤l 15453
¾\ŪÅv­­ 255
µù¥U 2007-1-14
¥Î¤áµù¥U¤Ñ¼Æ 6284
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 0

42.67.69.203
µoªí©ó 2014-9-20 19:53  ¸ê®Æ ¥D­¶ ¤å¶° ¨p¤H°T®§ 
¤@¦¸·l¥¢¡CDon't worry !
³»³¡
Joe
¦P¾Ç




UID 2
ºëµØ 0
¿n¤À 0
©«¤l 2090
¾\ŪÅv­­ 99
µù¥U 2011-3-16
¥Î¤áµù¥U¤Ñ¼Æ 4761
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1941

61.228.160.18
µoªí©ó 2014-9-21 09:09  ¸ê®Æ ¨p¤H°T®§ 
Qoo  ®á¨Ó«H   

Joe ®á
¥i¥H½Ð°Ý§A
±q«ùªÑgsk¥H¨Ó
ªÑ»ù¤@ª½¤U¶^
¬Q¤Ñ¦³¬Ý¨ìÃļt­n½ß¤¤°ê¤T¤Q»õ
½Ð°Ýgsk¬O¤£¬O¦b¨«¤U©Y©O
ÁÂÁ±z
³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.70.110
µoªí©ó 2014-9-21 09:17  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
³Ì¦n¦A¶^­Ó15%
§Ú¦n¦b¸É¤@ÂI¶i¨Ó.

QUOTE:
­ì©«¥Ñ joe ©ó 2014-9-21 09:09 µoªí
Qoo  ®á¨Ó«H   

Joe ®á
¥i¥H½Ð°Ý§A
±q«ùªÑgsk¥H¨Ó
ªÑ»ù¤@ª½¤U¶^
¬Q¤Ñ¦³¬Ý¨ìÃļt­n½ß¤¤°ê¤T¤Q»õ
½Ð°Ýgsk¬O¤£¬O¦b¨«¤U©Y©O
ÁÂÁ±z

³»³¡
chenleon1 (leon)
·|­û
Rank: 1



UID 451
ºëµØ 0
¿n¤À 0
©«¤l 1532
¾\ŪÅv­­ 10
µù¥U 2011-5-26
¥Î¤áµù¥U¤Ñ¼Æ 4690
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1840

125.230.91.160
µoªí©ó 2014-9-24 15:04  ¸ê®Æ ¤å¶° ¨p¤H°T®§ 
Dr. Reddy¡¦s Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) business and custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL¡¦s new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma. On March 27, 2012, DRL launched quetiapine fumarate tablets. On March 2, 2012, it launched ziprasidone hydrochloride capsules. On October 24, 2011, DRL launched olanzapine tablets. On July 25, 2011, it launched fondaparinux sodium injection.


³»³¡